Júlia Teixeira Cottas de Azevedo, Thalita Cristina de Mello Costa, Keli Cristina Lima, Thiago Trovati Maciel, Patrícia Vianna Bonini Palma, Luiz Guilherme Darrigo-Júnior, Carlos Eduardo Setanni Grecco, Ana Beatriz P L Stracieri, Juliana Bernardes Elias, Fabiano Pieroni, Renato Luiz Guerino-Cunha, Ana Cristina Silva Pinto, Gil Cunha De Santis, Dimas Tadeu Covas, Olivier Hermine, Belinda Pinto Simões, Maria Carolina Oliveira, Kelen Cristina Ribeiro Malmegrim
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only currently available curative treatment for sickle cell disease (SCD). However, the effects of HSCT on SCD pathophysiology are poorly elucidated. Here, we assessed red blood cell (RBC) adhesiveness, intensity of hemolysis, vascular tone markers and systemic inflammation, in SCD patients treated with allogeneic HSCT. Thirty-two SCD patients were evaluated before and on long-term follow-up after HSCT. Overall survival was 94% with no severe (grade III-IV) graft- vs -host disease and a 22% rejection rate (graft failure)...
2021: Frontiers in Immunology